BACKGROUND: Obesity in women has been associated with a variety of factors, including genetic predisposition, social class, early age at menarche, exercise, alcohol consumption and diet. Obesity is a risk factor for the occurrence and the recurrence of breast cancer in postmenopausal women, perhaps because of increased exposure to estrogen, insulin and insulin-like growth factors (IGFs). The progesterone receptor (PR) and the steroid hormone receptor coactivator pCIP/ACTR/AIB1/TRAM1/RAC3 (AIB1) are hypothesized to mediate signaling crosstalk between these hormonal pathways. Polymorphisms in both genes have been described and their association with breast cancer risk reported. If genetic factors contribute to obesity, and the PR and AIB1 genes influence estrogenic, insulin and IGF pathways, then genetic patterns resulting from PR and AIB1 polymorphisms may be associated with obesity in postmenopausal women. OBJECTIVE: We compared the PR and AIB1 genotypes of postmenopausal women with breast cancer with demographic, disease-related, reproductive, lifestyle and dietary variables in terms of the strength of their relationship with obesity (BMIZ30 kg/m 2 ). SUBJECTS: A total of 301 postmenopausal women previously diagnosed with Stage I, II or IIIA breast cancer, who are enrolled in the Women's Healthy Eating and Living (WHEL) study (age: 34.5-70.8 y, BMI: 17.8-54.6 kg/m 2 ). MEASUREMENTS: The PR polymorphism PROGINS was identified by PCR. The length of the AIB1 polyglutamine repeat was determined by PCR and nondenaturing gel electrophoresis or DNA sequencing. BMI was obtained at the baseline clinic visit upon entry into the WHEL study. Information about date of diagnosis, stage of disease, tumor hormone receptor status and adjuvant treatment received were obtained from medical records. Reproductive, menstrual history, demographic, family history of cancer, smoking history and exercise frequency and intensity information were obtained from questionnaires. Dietary and alcohol intake data came from four 24-h telephone recalls of food intake obtained at the study entry. RESULTS: The combined inheritance of PROGINS A1/A1 and AIB1 28/29, 28/30, 28/31, 29/29 or 29/30 (AIB1 LG) genotypes (adjusted odds ratio (OR) ¼ 2.22 (95% confidence interval 1.25-3.93)) and early age at menarche (o12 y) (adjusted OR ¼ 2.34 (1.12-4.86)) were each associated with the risk for obesity. Current use of tamoxifen ) and an alcohol intake Z10 g/day (adjusted OR ¼ 0.28 (0.11-0.77)) were inversely associated with BMI Z30 kg/m 2 . CONCLUSION: Early age at menarche and a PROGINS A1/A1 þ AIB1 LG genetic pattern had comparable levels of association with obesity in this cross-sectional sample of postmenopausal women with breast cancer. Since this was a cross-sectional rather than a case-control design, the association between PROGINS and AIB1 genotype and obesity found in this sample should be considered preliminary, and must be re-evaluated with a new and larger sample.
Introduction
Obesity in women has been associated with a variety of factors, including genetic predisposition, social class, early age at menarche, exercise, alcohol consumption and diet. 1 In postmenopausal women, obesity is an established risk factor for breast cancer. 2, 3 Obesity in both pre-and postmenopausal women who develop breast cancer has been shown in most, but not all, case-control and cohort studies to predict an increased risk for disease recurrence and death. [4] [5] [6] Both IGF-1 and estrogen are required for normal mammary development. 7 Increased body fat in postmenopausal women leads to increased synthesis of estrogen and higher levels of circulating estrogen. 8, 9 The continued exposure of the breast to increased levels of estrogen, insulin and insulinlike growth factors (IGFs) in these women contributes to their risk of breast cancer occurrence and recurrence. [7] [8] [9] [10] [11] [12] [13] [14] [15] The expression of the IGF-1 receptor (IGF-1R) is increased in breast cancer. 14 Two genes that mediate the interactions between the estrogen, insulin and IGF signaling pathways are the progesterone receptor (PR) and the steroid hormone receptor coactivator pCIP/ACTR/AIB1/TRAM1/RAC3 (AIB1). [16] [17] [18] [19] [20] [21] The AIB1 gene is amplified in about 10% of breast tumors, while its mRNA is overexpressed in about 64%. 18, 22 Both the PR and AIB1 regulate both ER-and IGF-mediated gene transcription. 16, 17, 23 Polymorphisms in both PR and AIB1 have been described and their individual relationships to breast cancer risk have been evaluated with both positive and negative results. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] We hypothesized that genetic differences in the PR and AIB1 would be associated with obesity in postmenopausal women because of their central role in mediating hormonal pathways associated with obesity. We evaluated the independent association of polymorphisms in these genes, both individually and in combination as a genetic pattern, with obesity in a cross-sectional study of 301 postmenopausal women with breast cancer.
Materials and methods
The parent WHEL study The Women's Healthy Eating and Living (WHEL) study is an NCI-funded multi-institutional randomized clinical trial of the effect of diet on breast cancer recurrence. Over 3000 women with Stage I (Z1 cm), II and IIIA breast cancer, diagnosed within the previous 4 y, have been enrolled and will be followed until the year 2006. All women had completed adjuvant treatment and radiation, and had no evidence of disease recurrence when they entered the study. At study entry, women were randomly assigned either to an intensive diet intervention or to a comparison control group. In this report, the women's study arm membership was not considered, because the variables we evaluated predated entry into the WHEL study.
Selection of postmenopausal sample
In 1999, an ancillary, separately funded study was initiated to measure circulating hormones, lipids and carotenoids in a subset of 400 WHEL study participants. This paper reports on the 301 women in the ancillary study, who were postmenopausal and had genotype data. Although the results of this ancillary study are not the focus of this report, it is pertinent to understanding how the sample of genotyped postmenopausal women was chosen. The women were selected from among those who had completed at least 1 y in the study, using a systematic quota system. The first 200 in each arm of the WHEL study who met the following additional criteria were selected: completed dietary assessments and blood collections at baseline and 1 y; no change in tamoxifen use during this time span; and approximately half younger than 50 y and half older than 50 y at enrollment.
Menopausal status was defined by conventional clinical criteria: absence of menses for at least 1 y at the time of study entry. 35 Although the genotyped women were postmenopausal by this criterion when they entered the study, they were not necessarily postmenopausal when their breast cancer was diagnosed. In all, 42% were younger than 45 y at diagnosis. Since adjuvant chemotherapy can result in ovulatory failure in premenopausal women, some of the younger women may have experienced an early menopause as a result of their chemotherapy.
Collection of personal information
Data-collection methods for WHEL study participants, including questionnaires used and a detailed description of 24-h telephone dietary recall protocols, are described elsewhere. 34 . The reproductive history, life history, lifestyle and dietary variables were also analyzed as categorical rather than continuous data. The following categories were used: menarche (o12 or Z12 y), age at first live birth (o20 or Z20 y or never), level of education (college graduate, yes or no), tamoxifen use (current vs previous or never), exercise frequency (o600 vs Z600 METS/week), alcohol intake (o10 g vs Z10g/day) and fat (o30% vs Z30% energy intake). Analyses were adjusted for ethnicity because of the small number of non-Caucasian women. Adjusted odds ratios (OR) and 95% Wald confidence limits for the risk of obesity were computed using SAS.
Results

Sample characteristics
The 301 genotyped women are comparable to the other 2149 postmenopausal WHEL study women in terms of age at diagnosis, BMI, disease stage, hormone receptor status, history of breast or ovarian cancer in first-degree relatives, education, ethnicity, adjuvant treatment received and tamoxifen use. However, the average length of time from diagnosis to entry into the WHEL study for the genotyped group was significantly greater at 2.371.0 vs 2.071.0 y (mean7s.d.) (P ¼ 0.001).
Relationship between BMI and the sample's demographic disease-related, lifestyle, life history and dietary characteristics Using the NIH weight classification scheme, 82 (28%) of the 301 women were obese, with a BMI Z30 kg/m 2 ; 100 (33%) were overweight, with a BMI between 25 and 29.99 kg/m 2 ; 177 (39%) had normal weight, with a BMI between 18.5 and 24.9 kg/m 2 ; and two (0.6%) were underweight with a BMIo18.5 kg/m 2 .
Univariate associations between BMI and the demographic, disease-related, reproductive history, lifestyle and dietary characteristics of the genotyped group are shown in Table 1 . Significant univariate associations with BMI were found for education (P ¼ 0.05), age at menarche (Po0.0001), exercise (P ¼ 0.002), alcohol intake (P ¼ 0.005) and dietary energy from fat (P ¼ 0.05). The associations for BMI and age at first live birth (P ¼ 0.08), ethnicity (P ¼ 0.07) and the current use of tamoxifen (P ¼ 0.06) failed to reach conventional levels of statistical significance. The PROGINS A1/A1 genotype, lacking the polymorphism, was found in 216/301 or 72% of the women. The A2/A2 genotype was found in only seven women (2%). For statistical analysis, women with the A2/A2 genotype were combined with A1/A2 heterozygotes.
Genotype frequencies
Glutamine repeat lengths in AIB1 ranged from 26 to 31. The 26, 28 and 29 repeat alleles were the most frequent. The most common allelotypes, in decreasing order of frequency, were 28/29 (43%), 29/29 (21%), 28/28 (15%), 26/28 (10%) and 26/29 (8%).
Relationships between progins and AIB1 genotypes and BMI We found significant relationships between BMI, PROGINS and AIB1 genotypes ( In all, 143 (48%) of the sample had inherited both the PROGINS A1/A1 and the AIB1 LG genotypes (PROGINS A1/ A1 þ AIB1 LG). Women with the PROGINS A1/A1 þ AIB1 LG genetic pattern had a significantly higher average BMI than women with other PROGINS and AIB1 genotype combina- Multivariate logistic regression models We used a multivariate logistic regression model to compare the association between BMI Z30 kg/m 2 and the PROGINS A1/A1 and AIB1 LG genotypes, individually and in combination, and those reproductive history, life history, lifestyle and dietary variables, whose univariate association with BMI was significant at Pr0.10 (Table 3) . Variables having a significant 
Discussion
In this paper, we have compared the association of genetic, demographic, disease-related, reproductive history, lifestyle and selected dietary variables to the risk for obesity in a cross-sectional study of 301 postmenopausal women with breast cancer who are within 4 y of diagnosis. Since obesity in postmenopausal women has been associated with increased exposure to estrogen, insulin and IGF, and since the PR and AIB1 genes are believed to mediate interactions between these hormonal pathways, we tested the hypothesis that genetic differences in the PR and AIB1 genes would be associated with obesity in this sample. Using multivariate logistic regression analysis, we found that the combined inheritance of the PROGINS A1/A1 and AIB1 LG genotypes and an early age at menarche (o12 y) were significant risk factors for obesity. The current use of tamoxifen and consumption of greater than 10 g/day of alcohol were inversely associated with obesity. Other variables included in the multiple logistic regression model, education, age at first live birth, amount of weekly exercise and dietary energy from fat, were not associated with obesity. The novel finding from this study is the association between postmenopausal obesity in women with breast cancer and a genetic pattern which combines the absence of the PR polymorphism PROGINS with longer polyglutamine repeats in the AIB1 gene. Women with the PROGINS A1/A1 genotype, who also inherited an AIB1 LG genotype, were 2.22 times as likely to have a BMI Z30 kg/m 2 as women who inherited other PROGINS and AIB1 genotype combinations (P ¼ 0.007). The PROGINS A1/A1 þ AIB1 LG genetic pattern, along with reaching menarche before age 12 y, were comparable risk factors for postmenopausal obesity. The PROGINS A1/A1 þ AIB1 LG genetic pattern was common and was found in 48% of the sample. The association between the inheritance of the PROGINS A1/A1 þ AIB1 LG genetic pattern with obesity in postmenopausal women with breast cancer has biological plausibility as well as clinical relevance. Both PR and AIB1 are postulated to mediate interactions between the estrogen, insulin and IGF hormonal pathways. Hyperinsulinemia, increased free IGF and increased circulating estrogen have each been associated with obesity in postmenopausal women. 13, 14, 21 Progesterone can induce the insulin and IGF-1 signaling cascades. 16 Steroid hormone receptor coactivators, such as AIB1, mediate gene expression by steroid hormones such as estrogen and progesterone. AIB1 is overexpressed in many breast cancers. 18, 22 Somatic growth retardation in AIB1 gene knockout mice implicates AIB1 in IGF-1-mediated regulation of somatic growth. 17 An association between the PROGINS and AIB1 polymorphisms and obesity has not been previously reported. Correlates of obesity in postmenopausal breast cancer L Wasserman et al However, both polymorphisms have been studied in relation to breast cancer risk. [24] [25] [26] [27] [28] [29] [30] [31] [32] A large case-control study 24 found
an association between the presence of the PROGINS allele and reduced risk for early onset breast cancer (o50 y), but several smaller studies failed to confirm this association. [26] [27] [28] AIB1 repeat lengths of 28 or longer have been associated with increased breast cancer risk in women carrying BRCA1 or BRCA2 mutations. 32 The reproductive history and lifestyle factors associated with obesity in this sample were early age at menarche and alcohol consumption Z10 g/day, and have been reported previously. Several large longitudinal studies have observed an increased risk for obesity in women whose menarche occurs before age 12.
1,36,37 Early age at menarche increases both premenopausal and postmenopausal breast cancer risk. 38, 39 The current use of tamoxifen was inversely related to the risk of obesity in this group of women with breast cancer. This association has not been previously described. The WHEL study has enrolled women from many sites throughout the southwestern United States. It is possible that differences in treatment practices with respect to use of adjuvant hormonal therapy and in the incidence of obesity across these sites confound the association.
In the present study, low consumption of alcohol, but not increased dietary fat or less physical activity, was associated with obesity in the multivariate logistic regression model. Several authors have noted a complex interaction between level of exercise, fat intake and obesity. [40] [41] [42] [43] Bias in selfreports of diet, alcohol intake, physical activity, energy expenditure and intake complicate the epidemiological analyses of risk factors for adult obesity, and lead to contradictory results across studies. We and others have observed that women who report either no alcohol consumption or less than one serving per day were at a greater risk for obesity than women who reported drinking one or more servings per day. 40 There are several limitations to this study. The association between PROGINS and AIB1 genotype and obesity found in this sample should be considered preliminary, and must be re-evaluated with a new and larger sample. This is a crosssectional rather than a case-control design. All the women had a diagnosis of breast cancer. As a result, the association between the PROGINS and AIB1 genotypes and obesity should not be interpreted in terms of breast cancer risk. Rather, we are suggesting a possible relationship with breast cancer outcome. The length of time between their diagnoses and their entry into the WHEL study varied from a few months to nearly 4 y. Thus, the measurement of their height and weight occurred at varying times after their breast cancer diagnosis and may not necessarily reflect their prediagnosis BMI. However, we found no systematic differences in average BMI as a function of age at diagnosis and length of time since diagnosis or adjuvant treatment history. The sample of women were drawn from a much larger and well-characterized cohort, who are primarily white, non-Hispanic, relatively well-educated and sufficiently concerned about their health to participate in a long-term dietary intervention study. Our sample was selected on a systematic rather than a random basis from the group of over 3000 women enrolled in the parent WHEL study. However, the demographic and disease-related characteristics of the 301 genotyped postmenopausal women are comparable to those of the other 2149 postmenopausal breast cancer survivors being followed in the WHEL study. Although all the women we studied were postmenopausal by self-report at the time their height, weight and waist circumferences were measured, they had not necessarily been postmenopausal when their breast cancer was diagnosed. Many of the women had received systemic adjuvant chemotherapy and the younger women may have experienced ovulatory failure. However, regardless of their menopausal status at the time of diagnosis, overweight and obese women with breast cancer who are now postmenopausal may well experience continuing and greater effects of estrogen due to increased estrogen synthesis in their body fat, and may be at a greater risk for breast cancer recurrence, regardless of their prediagnosis BMI or menopausal status. [4] [5] [6] 15 In addition to the PR and the AIB1 genetic pattern, we evaluated the univariate associations of 20 variables, reflecting the demographic factors, reproductive history, adjuvant treatment and dietary patterns, for their association with BMI. Significant associations with the risk for a BMI Z30 kg/ m 2 were found for three variables in addition to the PROGINS A1/A1 þ AIB1 LG genetic pattern. Thus, the possibility of making type I errors and finding significant associations by chance must temper any conclusions drawn. Disease-free survival of postmenopausal women with breast cancer varies as a function of postdiagnosis BMI. In a recent review of studies published since 1990, evaluating the association between BMI and breast cancer outcome, 17 of 26 studies found that increased BMI or body weight was a significant risk factor for recurrent disease or death or both; seven of the 26 studies found no association, while two studies reported an inverse relationship. 6 An earlier review, published in 1990, found postmenopausal obesity to be an independent, albeit modest predictor of decreased survival, especially in women with less advanced disease. 4 The WHEL study is designed to identify factors that may predict the outcome after breast cancer. WHEL study investigators are seeking to identify genetic and other factors that may be associated with disease recurrence in this group. Since obesity has been associated with an increased risk of disease recurrence in postmenopausal women with breast cancer, identification of genetic differences associated with obesity may ultimately have prognostic import.
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